Compare PLBC & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLBC | SCLX |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.2M | 35.2M |
| IPO Year | 2002 | 2020 |
| Metric | PLBC | SCLX |
|---|---|---|
| Price | $62.75 | $4.90 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $57.67 | N/A |
| AVG Volume (30 Days) | 34.8K | ★ 36.4K |
| Earning Date | 04-15-2026 | 04-10-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.79 | N/A |
| Revenue | N/A | ★ $30,253,000.00 |
| Revenue This Year | $25.59 | $122.52 |
| Revenue Next Year | $5.15 | $186.30 |
| P/E Ratio | $22.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.89 | $4.20 |
| 52 Week High | $64.00 | $34.27 |
| Indicator | PLBC | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 27.24 |
| Support Level | $60.00 | $4.20 |
| Resistance Level | $63.74 | $7.77 |
| Average True Range (ATR) | 1.16 | 0.30 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 85.39 | 5.93 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.